✦ LIBER ✦

Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia

✍ Scribed by Larrea, L; Martínez, J A; Sanz, G F; Martín, G; de la Rubia, J; Jiménez, C; Jarque, I; Cid, A; López, A; Sanz, M A

Book ID: 110054079
Publisher: Nature Publishing Group
Year: 1999
Tongue: English
Weight: 85 KB
Volume: 13
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2401278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

All-transretinoic acid plus low doses of

All-transretinoic acid plus low doses of cytarabine for the treatment of “poor-risk” acute myeloid leukemias

✍ A. Venditti; R. Stasi; M. Masi; G. Del Poeta; C. Cox; A. Franchi; D. Piccioni; A 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 163 KB

A randomized study of mitoxantrone plus

A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia

✍ S. Pavlovsky; J. Gonzalez Llaven; M. A. Garcia Martinez; P. Sobrevilla; M. Eppin 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 444 KB

Treatment of acute myeloblastic leukemia

Treatment of acute myeloblastic leukemia in adults. The GOELAM experience

✍ J. L. Harousseau; B. Pignon; F. Witz; V. Polin; Z. Tellier; P. Hurteloup; J. Y. 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 221 KB

Is cytarabine required in the treatment

Is cytarabine required in the treatment of acute promyelocytic leukemia?

✍ Lionel Adès; Pierre Fenaux 📂 Article 📅 2006 🏛 Current Science Inc. 🌐 English ⚖ 83 KB

Enhanced skin toxicity associated with t

Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia

✍ Zhang, Bingnan; Bolognia, Jean; Marks, Peter; Podoltsev, Nikolai 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 328 KB

Fludarabine, cytarabine, and G-CSF (FLAG

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia

✍ Montillo, Marco; Mirto, Salvatore; Petti, Maria Concetta; Latagliata, Roberto; M 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 2 views

Thirty-eight patients with primary resistant or relapsing acute myeloid leukemia (AML) were treated with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). Median age was 41 (range 11-70). Sixteen patients had AML that was primary resistant to induction treatment, while 22 wer